Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

NCT02646189 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: REP 2139-Ca
DRUG: Zadaxin
DRUG: Pegasys

Sponsor

Replicor Inc.